California Public Employees Retirement System lifted its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 23.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,200 shares of the company’s stock after acquiring an additional 3,300 shares during the period. California Public Employees Retirement System’s holdings in Crispr Therapeutics were worth $705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of CRSP. NEXT Financial Group Inc boosted its stake in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new stake in shares of Crispr Therapeutics in the third quarter worth approximately $26,000. US Bancorp DE boosted its stake in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the last quarter. Finally, BSW Wealth Partners acquired a new stake in shares of Crispr Therapeutics in the second quarter worth approximately $39,000. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ CRSP traded down $0.38 during mid-day trading on Tuesday, hitting $65.95. 693,862 shares of the stock were exchanged, compared to its average volume of 713,054. The company has a market cap of $3.61 billion, a P/E ratio of -19.17 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock’s fifty day simple moving average is $61.00 and its two-hundred day simple moving average is $49.02. Crispr Therapeutics AG has a twelve month low of $22.22 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, equities research analysts predict that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
CRSP has been the topic of several recent analyst reports. BidaskClub lowered Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research note on Monday, November 18th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Finally, Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $69.54.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Bollinger Bands
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.